Trial · NCT07913685
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in body weight (kg) | Week 12 | Observed change in body weight from baseline to week 12 in the group treated with liraglutide+LCD compared to dietary intervention alone. |
| Secondary | Proportion of subjects losing ≥ 5% of baseline body weight | Week 12 | Percentage of subjects losing at least 5% of baseline body weight after 12 weeks of treatment. |
| Secondary | Proportion of subjects losing ≥ 10% of baseline body weight | Week 12 | Percentage of subjects losing at least 10% of baseline body weight after 12 weeks of treatment. |
| Secondary | Change in waist circumference (cm) | Week 12 | Observed change in waist circumference from baseline to week 12. |
| Secondary | Change in insulin sensitivity measured in hyperinsulinemic euglycemic clamp | Week 12 | Observed change in insulin sensitivity measured in hyperinsulinemic euglycemic clamp from baseline to week 12. Insulin sensitivity will be expressed as whole-body glucose uptake normalized for fat-free mass. |
| Secondary | Change in indirect indices of insulin sensitivity: HOMA-IR | Week 12 | Observed change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) from baseline to week 12. |
| Secondary | Change in indirect indices of insulin sensitivity: Matsuda | Week 12 | Observed change in Matsuda index from baseline to week 12. |
| Secondary | Change in indirect indices of insulin sensitivity: FLAIS | Week 12 | Observed change in Fasting Laboratory Assessment of Insulin Sensitivity (FLAIS) index from baseline to week 12. FLAIS is an index of insulin sensitivity, calculated from RBC count, ALT, C-peptide, SHBG, adiponectin and IGFBP-1. Higher values of FLAIS reflect higher insulin sensitivity. |
| Secondary | Change in body composition: total fat mass (kg) | Week 12 | Observed change in total fat mass measured in dual-energy X-ray absorptiometry (DEXA) from baseline to week 12. |
| Secondary | Change in body composition: total lean mass (kg) | Week 12 | Observed change in total lean mass measured in dual-energy X-ray absorptiometry (DEXA) from baseline to week 12. |
| Secondary | Change in body composition: visceral adipose tissue mass (g) | Week 12 | Observed change in visceral adipose tissue mass measured in dual-energy X-ray absorptiometry (DEXA) from baseline to week 12. |
| Secondary | Change in body composition: subcutaneous adipose tissue mass (g) | Week 12 | Observed change in subcutaneous adipose tissue mass measured in dual-energy X-ray absorptiometry (DEXA) from baseline to week 12. |
| Secondary | Change in liver steatosis: CAP | Week 12 | Observed change in liver steatosis expressed as controlled attenuation parameter (CAP) measured with noninvasive transient elastography from baseline to week 12. |
| Secondary | Change in intrahepatic lipid content measured with proton magnetic resonance spectroscopy (%) | Week 12 | Observed change in intrahepatic lipid content measured with 1.5 T proton magnetic resonance spectroscopy from baseline to week 12. |
| Secondary | Change in intramuscular lipid content measured in proton magnetic resonance spectroscopy (%) | Week 12 | Observed change in intramuscular lipid content measured with 1.5 T proton magnetic resonance spectroscopy from baseline to week 12. |
| Secondary | Change in cytokine concentrations | Week 12 | Observed change in the concentrations of pro- and anti-inflammatory cytokines, adhesion molecules, endothelial markers and adipokines from baseline to week 12. |
| Secondary | Change in gene expression | Week 12 | Observed change in the expression of genes associated with insulin signaling and inflammation in peripheral blood mononuclear cells assessed with qPCR/NGS from baseline to week 12. |
| Secondary | Change in resting energy expenditure | Week 12 | Observed change in resting energy expenditure measured in indirect calorimetry from baseline to week 12. |
| Secondary | Change in Beck Depression Inventory score (BDI) | Week 12 | Observed change in depressive symptoms assessed using BDI from baseline to week 12. Total score: 0-63 points; higher scores reflect greater severity of depressive symptoms. |
| Secondary | Change in Hospital Anxiety and Depression Scale (HADS) | Week 12 | Observed change in depressive and anxiety symptoms assessed with HADS from baseline to week 12. Total score: 0-42 points; higher scores reflect greater severity of depressive and anxiety symptoms. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07913685/registered